Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

Alzheimer's & Dementia - Tập 14 - Trang 981-988 - 2018
Ron Brookmeyer1, Nada Abdalla1
1Department of Biostatistics, University of California, Los Angeles, CA, USA

Tóm tắt

AbstractIntroductionLifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten‐year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease.MethodsWe used a multistate model for the disease process together with US death rates.ResultsLifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90‐year old and 29.3% for a 65‐year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%.DiscussionMost persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.

Tài liệu tham khảo

10.1016/j.jalz.2011.03.003 10.1016/S1474-4422(09)70299-6 10.1016/j.jalz.2016.08.005 National Academies of Science, Engineering and Medicine, 2017, Preventing cognitive decline and dementia: A way forward 10.1016/S1474-4422(07)70291-0 10.1161/01.STR.0000199613.38911.b2 10.1016/j.jalz.2011.03.008 10.1016/j.jalz.2011.03.005 10.1126/science.1072994 10.1002/ana.23816 10.1007/s00401-014-1362-3 10.1038/nrneurol.2015.251 10.1016/S1474-4422(15)00323-3 10.1016/j.jalz.2017.10.009 10.1093/brain/awv029 Human Mortality Database. University of California Berkeley (USA) and Max Planck Institute for Demographic Research (Germany) Available at:www.mortality.orgAccessed January 4 2016. 10.3233/JAD-143078 10.1212/WNL.59.2.198 10.1001/archneurol.2009.80 10.1111/ene.12278 10.1111/jgs.14666 10.1002/sim.4187 Pfeiffer R., 2017, Absolute risk: methods and applications in clinical management and public health, monographs on statistics and applied probability 154, 10.1201/9781315117539 10.1093/oxfordjournals.aje.a009489 10.1007/BF00145007 10.1007/s13524-017-0598-7 10.1159/000087448 10.1080/01621459.2013.859076 10.1212/WNL.55.1.66 10.1016/j.jalz.2014.01.004 10.1212/WNL.0000000000000240 Murphy S.L., 2013, Deaths: Final data for 2010, Natl Vital Stat Rep, 61 10.1016/j.jalz.2007.04.381 10.1093/brain/awv283 Langa K.M., 2017, A comparison of the prevalence of dementia in the United States in 2000 and 2012, JAMA Intern Med, 77, 51, 10.1001/jamainternmed.2016.6807 10.1056/NEJMoa1504327 10.1212/WNL.49.6.1498 10.1002/ana.21843 10.1002/ana.22248 10.1016/S1474-4422(14)70194-2 10.1001/jama.2015.4668 10.1212/WNL.0000000000002923 10.2967/jnumed.113.120618 10.7326/M14-0496 10.2217/nmt.13.25 10.1016/j.neurobiolaging.2016.07.011
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 14

981-988

Thông tin tác giả